Amr Salah Omar
@aomar4646
Followers
50
Following
136
Media
1
Statuses
69
Joined May 2015
In a systematic review of 15 studies, VA-ECMO may provide meaningful survival benefits (42%) in carefully selected patients with severe, refractory septic shock/sepsis-induced cardiomyopathy. https://t.co/SFfvqhLJUY
@JCVAonline
@ANS_ALAMAMI
@aomar4646
0
4
12
automated IVC-DI mode demonstrated less reliability than the manual in ventilated cardiac surgery patients who were fluid responsive. @sehanoura73 @drpraveencs @AlaaRahhal13 @JCVAonline
1
0
1
Automated inferior vena cava distensibility index for assessing fluid responsiveness in ventilated patients after cardiac surgery: a prospective pilot comparative study. - Journal of Cardiothoracic and Vascular Anesthesia
jcvaonline.com
This study aimed to assess the accuracy of inferior vena cava distensibility index (IVC-DI) measurements, as well as the ability to track fluid responsiveness (FR) over time.
1
2
3
https://t.co/BPoeuyGtJw When medicine meets borders: a story of hope, and heartbreak, in the skies
link.springer.com
Intensive Care Medicine -
0
2
3
جامعة القاهرة تعلن في بيان حصول جهاز التنفس الصناعي المصري "إيزفينت" على الترخيص التجاري الرسمي ليُصبح أول جهاز تنفس صناعي للرعاية الحرجة يتم تصميمه وتطويره وتصنيعه بالكامل داخل مصر من قِبل كلية طب قصر العيني
97
290
3K
In a multicenter cohort study, SGLT2i use was associated with reduced POAF. #ACC25
@HMC_Qatar
@ynhhealth
@ROCRegional
@aomar4646
@Ashraf_Ahmed94 Presented by @MohanadShehadeh
https://t.co/iubetntOVE
0
3
6
Mortality of CS requiring VA-ECMO, regardless of IABP use, remains high; however, concomitant IABP use might minimize the effect of mortality predictors. @aomar4646
@JCVAonline
jcvaonline.com
The use of an intra-aortic balloon pump (IABP) has been suggested to unload the left ventricle while on venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock (CS), leading...
0
3
3
Levosimendan use in ECPR did not improve survival. Future well-designed randomized trials are warranted to investigate the potential benefit of levosimendan in the ECPR setting. @aomar4646
@bassantorabi
@JCVAonline
https://t.co/dpj4tuPXr3
jcvaonline.com
To examine whether levosimendan could improve survival in patients with cardiac arrest supported by extracorporeal cardiopulmonary resuscitation (ECPR).
1
3
9
A legendary figure in critical care understanding, innovation and clinical practice....
◾️In memory of Prof L Gattinoni, towering figure in ICM, profoundly shaping understanding of #ARDS & #ECMO. The “father" of prone position revolutionized MV with a pioneering "baby lung” concept. His legacy will guide/inspire for generations to come. 🔗 https://t.co/kjuqkQoPoc
0
1
1
Comparison of four intensive care scores in prediction of outcome after Veno-Arterial ECMO: A single-center retrospective study - Journal of Cardiothoracic and Vascular Anesthesia
jcvaonline.com
To assess the capability of the Acute Physiology and Chronic Health Evaluation II (APACHE-II), Sequential Organ Failure Assessment (SOFA) scores, Cardiac Surgery Score (CASUS), and Survival After...
0
1
2
Clinical Outcomes of Angiotensin II Therapy in Vasoplegic Shock: A Systematic Review and Meta-Analysis https://t.co/2hrZOfGGzk
#mdpilife via @Life_MDPI
@AlaaRahhal13
@ahmedshebani
@aomar4646
0
2
2
New Special Collection on "Enhancing Cardiac Surgical Critical Care". Interested in submitting? Find out more here: https://t.co/Svl4k0g1rY
#criticalcare #cardiac #callforpapers #openaccess
0
4
4
ونحن نحب الحياة وإذا ما استطعنا إليها سبيلا** ونرقص بين شهيدين نرفع مئذنة للبنفسج بينهما أو نخيلا**
92
1K
5K
Extracorporeal life support (ECLS) is increasingly used in the treatment of infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality. Read the full ECLS-SHOCK trial Research Summary:
0
21
50
#RCM - Vol. 24 No. 6 💥Review Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome 🎓from @RashaKaddoura2, @bassantorabi, Mohamed A Yassin, @aomar4646
#ACS #NOAC #DOAC #anticoagulation #antiplatelet 📪 https://t.co/UqfxKO8jWa
0
10
9
NOACs are increasingly used for off-licence indications, and continue to evolve as essential therapy in preventing and treating thrombotic events including indications in the setting of ischemic coronary disease. @mirvatalasnag
@aayshacader
@ZainabDakhil2
https://t.co/hGV3uLsxoC
imrpress.com
Acute coronary syndrome (ACS) is a leading cause of mortality worldwide. Despite optimal antiplatelet therapy recommendation after ischemic events, recurrent thrombotic complications rate remains...
5
15
28